Obesity - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 494 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Obesity - Overview 7
Obesity - Therapeutics Development 8
Obesity - Therapeutics Assessment 36
Obesity - Companies Involved in Therapeutics Development 54
Obesity - Drug Profiles 104
Obesity - Dormant Projects 439
Obesity - Discontinued Products 453
Obesity - Product Development Milestones 457
Appendix 467

List of Tables

Number of Products under Development for Obesity, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Obesity - Pipeline by Abeome Corp, H1 2017
Obesity - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
Obesity - Pipeline by Advinus Therapeutics Ltd, H1 2017
Obesity - Pipeline by Aegis Therapeutics LLC, H1 2017
Obesity - Pipeline by Akron Molecules AG, H1 2017
Obesity - Pipeline by Alize Pharma SAS, H1 2017
Obesity - Pipeline by Amabiotics SAS, H1 2017
Obesity - Pipeline by Amgen Inc, H1 2017
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
Obesity - Pipeline by AstraZeneca Plc, H1 2017
Obesity - Pipeline by Asubio Pharma Co Ltd, H1 2017
Obesity - Pipeline by Athersys Inc, H1 2017
Obesity - Pipeline by Biophytis SAS, H1 2017
Obesity - Pipeline by BioRestorative Therapies Inc, H1 2017
Obesity - Pipeline by Biozeus, H1 2017
Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Obesity - Pipeline by Braasch Biotech LLC, H1 2017
Obesity - Pipeline by C3J Therapeutics Inc, H1 2017
Obesity - Pipeline by Camurus AB, H1 2017
Obesity - Pipeline by Carmot Therapeutics Inc, H1 2017
Obesity - Pipeline by CohBar Inc, H1 2017
Obesity - Pipeline by CoMentis Inc, H1 2017
Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
Obesity - Pipeline by ConSynance Therapeutics Inc, H1 2017
Obesity - Pipeline by Corium International Inc, H1 2017
Obesity - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Obesity - Pipeline by DiscoveryBiomed Inc, H1 2017
Obesity - Pipeline by Eisai Co Ltd, H1 2017
Obesity - Pipeline by Eli Lilly and Company, H1 2017
Obesity - Pipeline by Esperion Therapeutics Inc, H1 2017
Obesity - Pipeline by Eternygen GmbH, H1 2017
Obesity - Pipeline by Evotec AG, H1 2017
Obesity - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Obesity - Pipeline by FibroGen Inc, H1 2017
Obesity - Pipeline by Genmedica Therapeutics SL, H1 2017
Obesity - Pipeline by Gila Therapeutics Inc, H1 2017
Obesity - Pipeline by Gilead Sciences Inc, H1 2017
Obesity - Pipeline by GlaxoSmithKline Plc, H1 2017
Obesity - Pipeline by Glucox Biotech AB, H1 2017
Obesity - Pipeline by GTx Inc, H1 2017
Obesity - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Obesity - Pipeline by Immungenetics AG, H1 2017
Obesity - Pipeline by Intarcia Therapeutics Inc, H1 2017
Obesity - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Obesity - Pipeline by Ixchel Pharma LLC, H1 2017
Obesity - Pipeline by Jenrin Discovery Inc, H1 2017
Obesity - Pipeline by Johnson & Johnson, H1 2017
Obesity - Pipeline by Laboratorios Silanes SA de CV, H1 2017
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2017
Obesity - Pipeline by Leading BioSciences Inc, H1 2017
Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
Obesity - Pipeline by M Pharmaceutical Inc, H1 2017
Obesity - Pipeline by Magnus Life Ltd, H1 2017
Obesity - Pipeline by MedImmune LLC, H1 2017
Obesity - Pipeline by Merck & Co Inc, H1 2017
Obesity - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
Obesity - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Obesity - Pipeline by NeuroNano Pharma Inc, H1 2017
Obesity - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
Obesity - Pipeline by NIBEC, H1 2017
Obesity - Pipeline by Nordic Bioscience A/S, H1 2017
Obesity - Pipeline by Novartis AG, H1 2017
Obesity - Pipeline by Novo Nordisk A/S, H1 2017
Obesity - Pipeline by ObeTherapy Biotechnology, H1 2017
Obesity - Pipeline by Omeros Corp, H1 2017
Obesity - Pipeline by OPKO Biologics Ltd, H1 2017
Obesity - Pipeline by OPKO Health Inc, H1 2017
Obesity - Pipeline by Pfizer Inc, H1 2017
Obesity - Pipeline by PharmaIN Corp, H1 2017
Obesity - Pipeline by Poxel SA, H1 2017
Obesity - Pipeline by Progenra Inc, H1 2017
Obesity - Pipeline by Prometheon Pharma LLC, H1 2017
Obesity - Pipeline by ReCyte Therapeutics Inc, H1 2017
Obesity - Pipeline by Renova Therapeutics Inc, H1 2017
Obesity - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
Obesity - Pipeline by Saniona AB, H1 2017
Obesity - Pipeline by Sanofi, H1 2017
Obesity - Pipeline by Seoul Pharma Co Ltd, H1 2017
Obesity - Pipeline by Shionogi & Co Ltd, H1 2017
Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
Obesity - Pipeline by Sorrento Therapeutics Inc, H1 2017
Obesity - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Obesity - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Obesity - Pipeline by Toray Industries Inc, H1 2017
Obesity - Pipeline by Umecrine AB, H1 2017
Obesity - Pipeline by Vicore Pharma AB, H1 2017
Obesity - Pipeline by Viking Therapeutics Inc, H1 2017
Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
Obesity - Pipeline by Xenetic Biosciences Inc, H1 2017
Obesity - Pipeline by XL-protein GmbH, H1 2017
Obesity - Pipeline by Yuyu Pharma Inc, H1 2017
Obesity - Pipeline by Zafgen Inc, H1 2017
Obesity - Pipeline by Zealand Pharma AS, H1 2017
Obesity - Dormant Projects, H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..1), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..2), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..3), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..4), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..5), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..6), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..7), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..8), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..9), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..10), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..11), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..12), H1 2017
Obesity - Dormant Projects, H1 2017 (Contd..13), H1 2017
Obesity - Discontinued Products, H1 2017
Obesity - Discontinued Products, H1 2017 (Contd..1), H1 2017
Obesity - Discontinued Products, H1 2017 (Contd..2), H1 2017
Obesity - Discontinued Products, H1 2017 (Contd..3), H1 2017